The study of protective effects of Empagliflozin in Mice with Induced Polycystic Ovary Syndrome

Purpose: Polycystic ovarian syndrome (PCOS) is the most common endocrine disorder affecting women of reproductive age. Oxidative stress plays a crucial role in the pathogenesis of PCOS. This study aimed to investigate the effects of empagliflozin as an antioxidant in mouse model of experimental PCOS. Methods: PCOS was induced in mice through daily subcutaneous injection of testosterone enanthate (۱ mg/۱۰۰g/ body weight.) for ۵ weeks. NMRI mice (۳ weeks old) were divided into four groups (n=۶): Control, empagliflozin, PCOS, and PCOS + empagliflozin (۳۰ mg/kg/body weight i.p.) was injected daily for ۴ weeks. Ovaries were collected for histopathological analysis, and serum concentrations of glucose, LDL, HDL, LDL/HDL, progesterone, testosterone, malondialdehyde (MDA) and the ferric ion reducing antioxidant power (FRAP) were measured. Results: A significant reduction in serum levels of MDA, glucose, LDL, LDL/HDL and testosterone was observed in the PCOS+ empagliflozin group compared to the PCOS group. Additionally, a significant increase in serum levels of HDL, antioxidant capacity and progesterone was found in the PCOS+ empagliflozin group compared to the PCOS group. The histopathological analysis showed that empagliflozin improved ovarian tissue alterations induced by PCOS. Conclusions: Our findings suggest that empagliflozin possesses antioxidant properties, improve folliculogenesis, and may be considered a potential therapeutic supplement for the treatment of PCOS.

کلیدواژه ها:

Polycystic ovary Syndrome ، Empagliflozin ، MDA ، Antioxidant capacity ، Mouse